Study Summary:
A randomized placebo-controlled, double-blind study of ly2216684 flexible-dose 12 to 18 mg once daily as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
Qualified Participants Must:
• Be at least 18 years of age
•
Have been diagnosed with Major Depressive Disorder
•
Currently be in a depressive episode
Qualified Participants May Receive:
Compensation for travel, food, and time.